Fig. 5

Concomitant expression of DKC1 and TERC and their impacts on Sunitinib response. The analyses were carried out on IMmotion 151 and IMmotion150 cohorts of ccRCC patients treated with Sunitinib. A and B Differences in TERC expression between DKC1-low and high groups in IMmotion151 (A) and IMmotion150 (B) cohorts. Left: all patients (both sexes); middle: female patients only and right: male patients only. C–E Differences in Sunitinib response and PFS between TERC-low and high groups in IMmotion151 cohort. (C) All patients (both sexes). D Female patients. E Male patients. F–H Differences in Sunitinib response and PFS between TERC-low and high groups in IMmotion150 cohort. (F) All patients (both sexes). G Female patients. H Male patients. I and J The evaluation of DKC1 and TERC as independent predictors for Sunitinib response and PFS. Univariate and multivariate COX regression analyses were performed on all patients (both sexes) (I) and female patients (J) from IMmotion151 cohort, respectively. CRPR: complete and partial response; SD: stable disease; PD: progressive disease. Panels A and B were evaluated using Wilcox sum test, while Fisher’s exact test was for C–H